C12N9/6478

COMPOSITIONS AND METHODS OF DIAGNOSING PANCREATIC CANCER

The present disclosure relates generally to detection of molecular biomarkers in a sample or diagnosis of a subject based upon detection or quantification of molecular biomarkers in a sample, specifically to the identification and use of biomarkers for pancreatic cysts.

ASPARTIC PROTEASES

Novel aspartic proteases, compositions containing these proteases and uses thereof are disclosed.

METHOD OF MANUFACTURING MEMBRANE PROTEIN AND UTILIZATION THEREOF

In order to provide a membrane protein production method which does not require the step of solubilizing a membrane protein and which allows the membrane protein having an excellent quality to be obtained with a high yield, a method in accordance with an embodiment of the present invention includes: a step (a) of preparing a reaction solution for cell-free protein synthesis, the reaction solution containing (i) a template nucleic acid which encodes the membrane protein, (ii) a lipid, and (iii) a detergent which is contained at a concentration equal to or higher than a critical micelle concentration; and a step (b) of synthesizing the membrane protein while the concentration of the detergent in the reaction solution is maintained at a concentration equal to or higher than a critical micelle concentration.

METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS

Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologically active fragment thereof. Such methods and compositions may be employed to reduce, prevent, degrade and/or eliminate amyloid formation in the lysosome and/or extracellularly.

COMPOSITIONS AND METHODS OF DIAGNOSING PANCREATIC CANCER

The present disclosure relates generally to detection of molecular biomarkers in a sample or diagnosis of a subject based upon detection or quantification of molecular biomarkers in a sample, specifically to the identification and use of biomarkers for pancreatic cysts.

Expression sequences

An isolated nucleic acid encoding a leader, which has a specific sequence, an isolated leader peptide encoded by such nucleic acid, an expression cassette comprising such nucleic acid encoding a leader operably linked to a nucleic acid sequence encoding a POI, a recombinant yeast host cell or a vector comprising such expression cassette, a method of producing a POI in such yeast host cell, and further the use of the specific nucleic acid for the secretion of a POI from a host cell and/or to increase the secretion of a POI from a host cell.

BACE1 INHIBITOR PEPTIDES

The present invention relates to dual-site BACE1 inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

EXPRESSION SEQUENCES
20180135092 · 2018-05-17 ·

An isolated nucleic acid encoding a leader, which has a specific sequence, an isolated leader peptide encoded by such nucleic acid, an expression cassette comprising such nucleic acid encoding a leader operably linked to a nucleic acid sequence encoding a POI, a recombinant yeast host cell or a vector comprising such expression cassette, a method of producing a POI in such yeast host cell, and further the use of the specific nucleic acid for the secretion of a POI from a host cell and/or to increase the secretion of a POI from a host cell.

Animal Model With Rapid Onset Of Alzheimer's Amyloid Beta Plaque Pathology
20240408246 · 2024-12-12 ·

Provided herein are compositions comprising a nucleic acid encoding amyloid-beta precursor protein and/or a nucleic acid encoding presenilin-1, cells comprising the compositions, animals comprising the compositions, methods of making the cells and animals, methods of modeling Alzheimer's disease, methods of assessing a therapeutic candidate for the treatment of Alzheimer's disease or amelioration of a symptom or phenotype of Alzheimer's disease, and methods of assessing a therapeutic candidate for the prevention of Alzheimer's disease or prevention of a symptom or phenotype of Alzheimer's disease.

MILK CLOTTING ASPARTIC PROTEASE ENZYME COMPOSITION

A liquid or dried granulated milk clotting aspartic protease enzyme composition comprising added polypeptides/proteins. The polypeptides/proteins may be animal-derived (e.g. whey, lactalbumin, transferrin, casein, ovalbumin, gelatin, blood), vegetable-derived (soy, pea, corn, potato, hemp, rice, wheat, peanut, sun flower, rape seed) or algae proteins (e.g. spirulina). Addition of protein in several instances increases activity of the enzyme and simultaneously improves physical stability.